Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham PlcfiledCriticalSmithkline Beecham Plc
Publication of AR006871A1publicationCriticalpatent/AR006871A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
El uso de un antagonista de leptina en la fabricación de un medicamento para el tratamiento de trastornos resultantes de las deficiencias en lasecreción de insulina, hiperglicemia y resistencia a la insulina.The use of a leptin antagonist in the manufacture of a medicament for the treatment of disorders resulting from deficiencies in insulin secretion, hyperglycemia, and insulin resistance.
ARP970101725A1996-04-261997-04-25
USE OF A LEPTIN ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT
AR006871A1
(en)
C-21 Modified Epothiolones, Methods of Making and Using Them, and Use of a Pharmaceutical Composition in the Treatment of Cancerous or Other Proliferative Diseases
Use of a pyrrolidine acetamide derivative in the manufacture of a medicament for the treatment of disorders of the central nervous system, and a pharmaceutical composition
FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, USE OF FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, METHOD FOR THE TREATMENT OF SYMPTOMS AND DISEASES, DISTRIBUTION OF MEDICINAL AND THERAPEUTIC AGENTS FOR THE TREATMENT OF SYMPTOMS AND DISEASES IN COMBINATION
PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A TRAMADOL COMPOUND AND ANTI-CONVULSIVE DRUG AND USE OF THE COMBINATION TO PREPARE A MEDICINAL PRODUCT
COMPOUNDS DERIVED FROM STEROIDS 17 ALPHA-FLUORO RENTED, WITH ANTIGESTAGENA ACTIVITY; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE OF THE COMPOUND IN THE PREPARATION OF AN ANTIESTROGENIC MEDICINAL PRODUCT, FOR THE TREATMENT OF DISMENORREA
glp-2 analog, glp-human peptide analog, peptide, pharmaceutical composition, use of a glp-2 analog, and, process for identifying intestinetrophic glp-2 analogs.
USE OF ASCORBIL-GAMMA-LINOLENATE OR ASCORBIL-DIHOMO-GAMMA-LINOLENATE FOR THE TREATMENT OF ASTHMA, CANCER, CARDIOVASCULAR DISEASES AND ANTI-INFLAMMATORIES.
A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
USE OF THE SAREDUTANT AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF USEFUL MEDICATIONS IN THE TREATMENT OR PREVENTION OF SUCCESSFUL HUMOR DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS
Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation